{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Open+Surgery&page=6", "query": { "condition": "Open Surgery", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 566, "total_pages": 57, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Open+Surgery&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Open+Surgery&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T18:10:44.055Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02014844", "title": "Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "250 mg/m2 aldoxorubicin", "type": "DRUG" }, { "name": "350 mg/m2 aldoxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2014-03", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2024-05-29", "last_synced_at": "2026-10-26T18:10:44.055Z", "location_count": 4, "location_summary": "Duarte, California • Santa Monica, California • New Orleans, Louisiana + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02014844" }, { "nct_id": "NCT04286438", "title": "Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hemorrhage", "Urgent Surgery", "Invasive Procedure" ], "interventions": [ { "name": "Bentracimab (PB2452) Infusion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SFJ Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 226, "start_date": "2020-07-15", "completion_date": "2024-09-09", "has_results": false, "last_update_posted_date": "2024-10-21", "last_synced_at": "2026-10-26T18:10:44.055Z", "location_count": 9, "location_summary": "Jacksonville, Florida • Lexington, Kentucky • Baltimore, Maryland + 6 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" }, { "city": "North Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04286438" }, { "nct_id": "NCT01500135", "title": "Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment of Needle Hole Bleeding in Vascular Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bleeding" ], "interventions": [ { "name": "TachoSil®", "type": "DRUG" }, { "name": "Surgicel® Original", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2012-03", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2017-02-08", "last_synced_at": "2026-10-26T18:10:44.055Z", "location_count": 37, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Long Beach, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01500135" }, { "nct_id": "NCT04308395", "title": "Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Basal Cell Nevus Syndrome" ], "interventions": [ { "name": "Patidegib Topical Gel, 2%", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sol-Gel Technologies, Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 108, "start_date": "2020-06-03", "completion_date": "2021-07-14", "has_results": true, "last_update_posted_date": "2024-09-24", "last_synced_at": "2026-10-26T18:10:44.055Z", "location_count": 17, "location_summary": "Fremont, California • Newport Beach, California • New Haven, Connecticut + 14 more", "locations": [ { "city": "Fremont", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Ormond Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04308395" }, { "nct_id": "NCT01490931", "title": "Intranasal Ketorolac for Postsurgical Pain in Dental Implant Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Acute Pain" ], "interventions": [ { "name": "Ketorolac Nasal Spray", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hersh, Elliot V., DMD, MS, PhD", "sponsor_class": "INDIV", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 28, "start_date": "2011-11", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2014-05-09", "last_synced_at": "2026-10-26T18:10:44.055Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01490931" }, { "nct_id": "NCT00853905", "title": "Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery?", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Glaucoma" ], "interventions": [ { "name": "Triesence", "type": "DRUG" }, { "name": "balanced salt solution BSS", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wills Eye", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 77, "start_date": "2009-02", "completion_date": "2012-01", "has_results": true, "last_update_posted_date": "2018-07-10", "last_synced_at": "2026-10-26T18:10:44.055Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00853905" }, { "nct_id": "NCT06312137", "title": "A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Sacituzumab tirumotecan", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Rescue medication", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 780, "start_date": "2024-04-03", "completion_date": "2034-10-23", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-26T18:10:44.055Z", "location_count": 51, "location_summary": "Little Rock, Arkansas • Springdale, Arkansas • Beverly Hills, California + 41 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06312137" }, { "nct_id": "NCT04462523", "title": "DEXTENZA for the Treatment of Postoperative Pain and Inflammation Following Vitreo-retinal Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Vitreo-Retinal Surgery" ], "interventions": [ { "name": "Dextenza 0.4Mg Ophthalmic Insert", "type": "DRUG" }, { "name": "Topical Prednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Patrick R. Oellers, MD", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 40, "start_date": "2020-01-03", "completion_date": "2022-03-31", "has_results": false, "last_update_posted_date": "2023-06-15", "last_synced_at": "2026-10-26T18:10:44.055Z", "location_count": 1, "location_summary": "Liverpool, New York", "locations": [ { "city": "Liverpool", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04462523" }, { "nct_id": "NCT05908786", "title": "A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Hepatocellular" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Tiragolumab", "type": "DRUG" }, { "name": "Tobemstomig", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2023-12-05", "completion_date": "2025-11-13", "has_results": true, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-26T18:10:44.055Z", "location_count": 5, "location_summary": "Los Angeles, California • Santa Monica, California • Washington D.C., District of Columbia + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "New York", "state": "New York" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05908786" }, { "nct_id": "NCT06833320", "title": "Propranolol Treatment for Postoperative Chylothorax", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Postoperative Chylothorax", "Congenital Heart Disease", "Open Heart Surgery", "Chylothorax" ], "interventions": [ { "name": "Propranolol Hydrochloride", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "June Wu", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Days", "maximum_age": "18 Years", "sex": "ALL", "summary": "7 Days to 18 Years" }, "enrollment_count": 50, "start_date": "2025-09-09", "completion_date": "2031-01-01", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-10-26T18:10:44.055Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06833320" } ] }